Facing pressure from both investors and regulators, banks and wealth managers are turning to pass-through voting mechanisms to reclaim shareholder influence and align stewardship with client values, even within passively managed funds.
Hawxhurst LLP has filed a federal lawsuit against International Amusement Rides and Intamin Ltd., alleging the roller coaster manufacturers failed to pay $1.5 million in legal fees after the firm defended them in high-stakes intellectual property battles.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
Despite posting strong quarterly results and outperforming major indices over the past year, U.S. Bancorp's stock is met with a measured 'Moderate Buy' consensus from analysts, highlighting a divergence between performance and sentiment.
NYCHA workers in Williamsburg made a horrific discovery on Sunday morning, finding a woman's dismembered remains inside a heavy bag in a building basement, sending shockwaves through the community.
A volatile January has underscored a stark shift for investors: political shocks emanating from Washington now pose a greater threat to portfolios than traditional economic or earnings concerns, reshaping risk calculus across global markets.
Specialty insurer Kinsale Capital Group continues to outpace broader industry growth in key metrics, driven by its focus on underserved, higher-risk markets. However, its premium valuation and recent stock volatility have intensified debate among investors about its long-term sustainability.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
Goldman Sachs raises Sweetgreen's price target to $5.60, citing policy tailwinds for consumer spending, even as it maintains a Sell rating. The salad chain's expansion and strong revenue growth continue to draw investor attention.
Analyst firm Benchmark increased its price target for specialty food distributor The Chefs' Warehouse (CHEF) to $84, maintaining a Buy rating. The move follows strong operational performance, including domestic acquisitions and double-digit international growth in the Middle East.
Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.
Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
Russia's premier cryptocurrency miner, BitRiver, faces insolvency proceedings as its CEO is placed under house arrest, marking a dramatic fall for a firm already crippled by international sanctions and mounting legal disputes.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
